All In Biotech

Drugs by condition

Drugs approved for immune thrombocytopenia

Brand-name prescription drugs and biologics whose FDA label lists immune thrombocytopenia as an approved use. Matched on the label phrases: "immune thrombocytopenia".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

8

Still marketed, NDA or BLA

Drug classes

3

Novel drugs

5

New molecular entities and new biologics

In development

17

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for immune thrombocytopenia.

  • Wayrilz (Rilzabrutinib) · Genzyme Corp NovelOrphanAug 29, 2025
  • Doptelet Sprinkle (Avatrombopag Maleate) · Akarx INC OrphanJul 24, 2025
  • Alvaiz (Eltrombopag Choline) · Teva Pharms INC Nov 29, 2023
  • Doptelet (Avatrombopag Maleate) · Akarx INC NovelPriority reviewOrphanMay 21, 2018
  • Tavalisse (Fostamatinib Disodium) · Rigel Pharms NovelOrphanApr 17, 2018

All approved drugs for immune thrombocytopenia, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 9 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Kinase Inhibitor (1)

  • Wayrilz Rilzabrutinib · Genzyme Corp · 2025

Thrombopoietin Receptor Agonist (1)

  • Nplate Romiplostim · Amgen · 2008

Class not listed in FDA's data (6)

  • Doptelet Avatrombopag Maleate · Akarx INC · 2018
  • Tavalisse Fostamatinib Disodium · Rigel Pharms · 2018
  • Promacta Eltrombopag Olamine · Novartis · 2008
  • Doptelet Sprinkle Avatrombopag Maleate · Akarx INC · 2025
  • Alvaiz Eltrombopag Choline · Teva Pharms INC · 2023
  • Promacta Kit Eltrombopag Olamine · Novartis · 2015

Drugs in development for immune thrombocytopenia

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • BirelentinibDZD8586Phase 37 trials

    Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)

  • CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials

    Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia

  • GR1803Velinotamig specified specified days., CLN-803Phase 37 trials

    Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • CM313Phase 36 trials

    Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness

  • Kedrion IVIG 10%KIg 10, Immune globulin 10% for administrationPhase 34 trials

    Kedrion S.p.A. · Primary Immunodeficiency Disease, Chronic Primary Immune Thrombocytopenia (ITP), Chronic Inflammatory Demyelinating Polyneuropathy

  • Zola-celBMS-986353, CC-97540Phase 33 trials

    Bristol Myers Squibb · Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis

  • HetrombopagPhase 32 trials

    Jiangsu HengRui Medicine Co., Ltd. · Chemotherapy-Induced Thrombocytopenia, Immune Thrombocytopenia

  • HMPL-523SovleplenibPhase 32 trials

    Hutchmed · Warm Antibody Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenia (ITP)

  • TQB3473Phase 32 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Primary Immune Thrombocytopenia

  • BudoprutugTNT119Phase 23 trials

    Climb Bio, Inc. · Primary Membranous Nephropathy, Systemic Lupus Erthematosus, Immune Thrombocytopenia (ITP)

  • CID-103Phase 23 trials

    CASI pharmaceuticals, Inc. · Chronic Immune Thrombocytopenia, Antibody Mediated Rejection

  • ESG206ESG206-2Phase 23 trials

    Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome

  • INCA000585Phase 21 trial

    Incyte · Immune Thrombocytopenia

  • NVG-2089Phase 21 trial

    Nuvig Therapeutics, Inc. · Immune Thrombocytopenia (ITP)

  • STSA-1301Phase 21 trial

    Jiangsu BioJeTay Biotechnology Co., Ltd. · Primary Immune Thrombocytopenia (ITP)

More on immune thrombocytopenia: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.